Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Gefitinib

The FDA approved gefitinib for non-small cell lung cancer (NSCLC) in May 2003. It is approved as monotherapy for the treatment of patients with locally advanced or metastatic NSCLC after failure of platinum and docetaxel chemotherapy.

Share:

Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.